Background Immunotherapy with T cells or bispecific T cell engagers is one promising approach to improve outcomes for patients with CD19-positive hematological malignancies. We had previously shown that T cells expressing bispecific T cell engagers that recognize CD19 and CD3 (CD19-ENG T cells) are activated in an antigen dependent manner, recruit resident T cells to tumors, and have anti-tumor...
